All Chemotherapy articles – Page 2
-
NewsDiabetes drug found to protect heart during cancer treatment
A commonly prescribed diabetes medication could significantly enhance long-term recovery prospects for cancer patients by reducing their risk of heart failure, a new study from the University of East Anglia (UEA) reveals.
-
ArticleRefining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
-
NewsPancreatic cancer suppressed by humanised anti-CKAP4 antibody
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
-
ArticleHow mRNA technology could revolutionise therapeutics
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
-
NewsThe emergence of targeted alpha therapy for glioblastoma
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
-
NewsPredicting persistent taxane-induced peripheral neuropathy
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
-
NewsOvercoming chemotherapy resistance in pancreatic cancer
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
-
News
B-ALL: combination therapy effectively controls high-risk subtypes
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
-
ArticleUsing AI to predict metastatic behaviour of NSCLC
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
-
NewsReversing malignant cancer cells to a normal state
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
-
NewsPotential for personalised, molecularly guided UTUC treatments
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
-
NewsOrganoid drug testing predicts bowel cancer treatment response
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
-
NewsHow the DA subtype of Wilms tumour resists chemotherapy
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
-
NewsThe potential of PD-L2 inhibitors for cancer treatment
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
-
News
New algorithm can predict when cancer will resist chemotherapy
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
-
ArticleTransforming cancer treatment for greatest impact
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.
-
NewsCBPUV nanoparticles show excellent anticancer activity
Novel self-assembled amino acid-based nanoparticles, loaded with doxorubicin, could evolve cancer treatment.
-
News
Perivascular fibroblasts support glioblastoma tumours
Glioblastomas can resist immunotherapy as perivascular fibroblasts support the creation of an immunosuppressive tumour environment.
-
ReportBeyond the lab: cancer research
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
-
NewsNew AI model can evaluate invasive breast cancer outcomes
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
- Previous Page
- Page1
- Page2
- Page3
- Next Page